Advertisement
Person › Details
Jan van de Winkel (Genmab A/S (CSE: GEN, Nasdaq: GMAB))
van de Winkel, Jan (Genmab 201106 CEO before CSO + Co-Founder before Medarex Europe)
Organisation | Genmab A/S (CSE: GEN, Nasdaq: GMAB) | |
Group | Genmab (Group) | |
Former/major organisation | Medarex Europe B.V. | |
Group | Bristol Myers Squibb (BMS) (Group) | |
Product | DuoBody technology platform (bispecific antibodies) | |
Product 2 | Arzerra® | |
Record changed: 2023-04-17 |
Advertisement
More documents for Jan van de Winkel
- [1] Argenx SE. (4/17/23). "Press Release: Argenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology and Oncology". Amsterdam....
- [2] BioNTech SE. (8/5/22). "Press Release: BioNTech and Genmab Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates". Mainz & Copenhagen....
- [3] Genmab A/S. (11/24/20). "Press Release: Genmab Announces Enapotamab Vedotin Update. Genmab Will Not Advance the Development of Enapotamab Vedotin". Copenhagen....
- [4] Genmab A/S. (6/10/20). "Press Release: Genmab and AbbVie Announce Broad Oncology Collaboration". Copenhagen & North Chicago, IL....
- [5] Genmab A/S. (12/19/19). "Press Release: Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics". Copenhagen & Tübingen....
- [6] Genmab A/S. (12/13/19). "Press Release: CHMP Issues Positive Opinion Recommending Darzalex (Daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma". Copenhagen....
- [7] Genmab A/S. (9/9/19). "Press Release: Genmab and Tempus Enter into Strategic Collaboration Agreement". Copenhagen....
- [8] Genmab A/S. (6/11/19). "Press Release: Genmab Signs Agreement with Janssen for Next-Generation CD38 Antibody, HexaBody-CD38". Copenhagen....
- [9] Genmab A/S. (1/22/19). "Press Release: Genmab Announces 2018 Net Sales Figures for Darzalex (Daratumumab)". Copenhagen....
- [10] Genmab A/S. (1/22/19). "Press Release: Genmab Announces Initiation of U.S. FDA Regulatory Submission for Label Expansion of Daratumumab in Combination with Lenalidomide and Dexamethasone in Front Line Multiple Myeloma". Copenhagen....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top